PIK3CA Genotype and Treatment Decisions in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
作者： David W. Cescon , Philippe L. Bedard
关键词: Multiplex 、 Genotype 、 Clinical trial 、 Medicine 、 Genotyping 、 Human Epidermal Growth Factor Receptor 2 、 Bioinformatics 、 Treatment decision making 、 Breast cancer 、 Exome
摘要: Genotyping of patient tumors has been rapidly incorporated into both clinical trials and practice over the last several years, with goal advancing personalized or precision cancer medicine. The crux these efforts is to identify actionable alterations— genetic changes that can be used guide individualized treatment. Dramatic advances in sequencing technologies DNA isolation methods now enable multiplex hotspot mutation testing targeted exome se
sci-hub.se 参考文章(36)
Francisco J. Esteva, Hua Guo, Siyuan Zhang, Cesar Santa-Maria, Steven Stone, Jerry S. Lanchbury, Aysegul A. Sahin, Gabriel N. Hortobagyi, Dihua Yu, PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. American Journal of Pathology. ,vol. 177, pp. 1647- 1656 ,(2010) , 10.2353/AJPATH.2010.090885
Martine J Piccart-Gebhart, Andrew Peter Holmes, Jose Baselga, Evandro De Azambuja, Amylou C Dueck, Giuseppe Viale, Jo Anne Zujewski, Aron Goldhirsch, Sergio Santillana, Kathleen I Pritchard, Antonio C Wolff, Christian Jackisch, Istvan Lang, Michael Untch, Ian E Smith, Frances Boyle, Binghe Xu, Henry Leonidas Gomez, Richard D Gelber, Edith A Perez, None, First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). Journal of Clinical Oncology. ,vol. 32, pp. 502- 502 ,(2014) , 10.1200/JCO.2014.32.18_SUPPL.LBA4
M Cizkova, M-E Dujaric, J Lehmann-Che, V Scott, O Tembo, B Asselain, J-Y Pierga, M Marty, P de Cremoux, F Spyratos, I Bieche, Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab British Journal of Cancer. ,vol. 108, pp. 1807- 1809 ,(2013) , 10.1038/BJC.2013.164
Teemu T. Junttila, Robert W. Akita, Kathryn Parsons, Carter Fields, Gail D. Lewis Phillips, Lori S. Friedman, Deepak Sampath, Mark X. Sliwkowski, Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941 Cancer Cell. ,vol. 15, pp. 429- 440 ,(2009) , 10.1016/J.CCR.2009.03.020
E. Razis, M. Bobos, V. Kotoula, A. G. Eleftheraki, H. P. Kalofonos, K. Pavlakis, P. Papakostas, G. Aravantinos, G. Rigakos, I. Efstratiou, K. Petraki, D. Bafaloukos, I. Kostopoulos, D. Pectasides, K. T. Kalogeras, D. Skarlos, G. Fountzilas, Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer Breast Cancer Research and Treatment. ,vol. 128, pp. 447- 456 ,(2011) , 10.1007/S10549-011-1572-5
Katrien Berns, Hugo M. Horlings, Bryan T. Hennessy, Mandy Madiredjo, E. Marielle Hijmans, Karin Beelen, Sabine C. Linn, Ana Maria Gonzalez-Angulo, Katherine Stemke-Hale, Michael Hauptmann, Roderick L. Beijersbergen, Gordon B. Mills, Marc J. van de Vijver, René Bernards, A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. ,vol. 12, pp. 395- 402 ,(2007) , 10.1016/J.CCR.2007.08.030
Vandana G. Abramson, M. Cooper Lloyd, Tarah Ballinger, Melinda E. Sanders, Liping Du, Darson Lai, Zengliu Su, Ingrid Mayer, Mia Levy, Delecia R. LaFrance, Cindy L. Vnencak-Jones, Yu Shyr, Kimberly B. Dahlman, William Pao, Carlos L. Arteaga, Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling Breast Cancer Research and Treatment. ,vol. 145, pp. 389- 399 ,(2014) , 10.1007/S10549-014-2945-3
José Baselga, Javier Cortés, Seock-Ah Im, Emma Clark, Graham Ross, Astrid Kiermaier, Sandra M. Swain, Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive, First-Line Metastatic Breast Cancer Journal of Clinical Oncology. ,vol. 32, pp. 3753- 3761 ,(2014) , 10.1200/JCO.2013.54.5384
Ian E. Krop, Patricia LoRusso, Kathy D. Miller, Shanu Modi, Denise Yardley, Gladys Rodriguez, Ellie Guardino, Michael Lu, Maoxia Zheng, Sandhya Girish, Lukas Amler, Eric P. Winer, Hope S. Rugo, A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine Journal of Clinical Oncology. ,vol. 30, pp. 3234- 3241 ,(2012) , 10.1200/JCO.2011.40.5902
Keith N Ogston, Iain D Miller, Simon Payne, Andrew W Hutcheon, Tarun K Sarkar, Ian Smith, A Schofield, Steven D Heys, A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. The Breast. ,vol. 12, pp. 320- 327 ,(2003) , 10.1016/S0960-9776(03)00106-1